Olatec Therapeutics Employee Directory
Biotechnology ResearchNew York, United States11-50 Employees
Olatec Therapeutics is a Phase 2 clinical-stage biotechnology company developing oral therapies for inflammatory diseases. Its lead candidate, dapansutrile, is a proprietary specific inhibitor of the NLRP3 pathway and has progressed from discovery to later-stage clinical development across arthritis, diabetes, neuroinflammatory diseases, and cancer. Early human data indicate the compound can safely modulate the immune system to help restore immune balance, potentially impacting disease progression and prognosis. The company has published preclinical and clinical studies in leading medical journals and conducts trials at international centers of excellence. Olatec operates in the United States and Europe, with offices in New York City and the Netherlands; in October 2025, Andy Cunningham was appointed to the board of directors.